Sameer Mir, Ph.D

Dr. Sameer Mir is a Postdoctoral Research Fellow at the National Institutes of Health (NIH), Bethesda, USA, specializing in cancer immunotherapy and molecular oncology. With a Ph.D. in Biological Sciences from the Academy of Scientific and Innovative Research (AcSIR), New Delhi, India, Dr. Mir has made significant contributions to cancer research. His work primarily focuses on developing next-generation targeted immunotherapies for malignant mesothelioma and gastrointestinal cancers, including establishing patient-derived xenograft models to explore mesothelin-directed therapies.

Publications

Dr. Mir has authored several impactful publications in high-impact journals, including:

• Clinical and Translational Medicine on CAR-T cell therapy for gastrointestinal carcinomas.

• Studies on breast cancer stem cells and small molecule inhibitors in Journal of Medicinal Chemistry and International Journal of Biological Macromolecules.

• Research on mitochondrial-mediated apoptosis and plant-based anticancer compounds in journals like Scientific Reports and Current Topics in Medicinal Chemistry.

1. Mir Sameer, Venugopalan A, Zhang J, Nair NU, Sengupta M, Khanal M, Stathopoulou C, Jiang Q, Hassan R. Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas. Clinical and Translational Medicine. 2024 Nov;14(11):e70057. doi: 10.1002/ctm2.70057. PMID: 39548594; PMCID: PMC11567854. IF= 10.2.

2. P Dar, Sameer A. Mir, J Bhat, Hamid, L Singh, F Malik, T Dar: An anti-cancerous protein fraction from Withania somnifera induces ROS-dependent mitochondria-mediated apoptosis in human MDA-MB-231 breast cancer cells. International Journal of Biological Macromolecules. DOI:10.1016/j.ijbiomac.2019.05.120. IF= 8.2.

3. U Singh, G Chashoo, S Khan, P Mahajan, Sameer A Mir, S Bharate, S Madishetti, U Nandi, G Singh, D Mondhe, S Bhushan, F Malik, S Mignani, R Vishwakarma, P Singh: Design of Novel 3-Pyrimidinylazaindole based CDK2/9 Inhibitors with Potent In-vitro and In-vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. Journal of Medicinal Chemistry.DOI:10.1021/acs.jmedchem.7b00663. IF= 8.03.

4. B Wadhwa, M Paddar , S Khan , Sameer Mir , P Calrke , A Grabowska , Devanahalli Vijay, Fayaz Malik. AKT isoforms have discrete expression in Triple Negative breast cancers and roles in cisplatin sensitivity. Oncotarget. doi.org/10.18632/oncotarget.27746. IF= 3.8.

5. Khan, S.U., Pathania, A.S., Wani, A….Mir S, J Kour.et al. Activation of lysosomal mediated cell death in the course of autophagy by mTORC1 inhibitor. Scientific Reports 12, 5052 (2022). https://doi.org/10.1038/s41598-022-07955-1. IF= 3.8.

6.        G Ahmad, M Masoodi, N Tabassum, Sameer Ahmad Mir, J Mir,  In-vivo Hepatoprotective Potential of Various Extracts Obtained from Floral Spikes of Prunella vulgaris L. Journal of Ayurveda and Integrative Medicine - doi: 10.1016/j.jaim.2019.08.003. IF= 2.4.

7. M Rehan, Shafiullah, Sameer A. Mir. Structural diversity, Natural sources and Pharmacological potential of plant based saponins with special focus on anticancer activity- A review. Medicinal chemistry Research- doi.org/10.1007/s00044-020-02600-w. IF= 2.6.

8. G Ahmad, Sameer A Mir, L Anand, F Malik, A Ali.Myricanol-9-acetate, a novel naturally occurring derivative of myricanol, induces ROS dependent mitochondrial-mediated Apoptosis in MCF-7 cancer cells. Current topics in medicinal chemistry. IF= 3.5.

9. G Ahmad, S Khan, Sameer A. Mir, M Iqbal, N Dhiman, F Malik, Ali. Myrica esculenta-A Comprehensive Review of its Phytochemistry Pharmacology and Nutritional Potential. Combinatorial Chemistry & High Throughput Screening-doi.org/10.2174/1386207325666220428105255. IF= 1.3

10. Tahirah Khaliq, Malik A Waseem, Sameer A Mir, Phalisteen Sultan, Fayaz A Malik, Qazi Parvaiz Hassan. Isolation and characterisation of pharmaceutically versatile molecules from Rumex dentatus and evaluation of their cytotoxic activity against human cancer cell lines. Natural Product Research-   doi.org/10.1080/14786419.2022.2092864. IF= 2.5

Awards and Honors

• Best Poster Award at the AIIMS conference on Translational Oncology (2020)

• Multiple national-level research fellowships in India, including NET-JRF, GATE, and ICMR-JRF.

• Visiting Research Fellow at Stem Cell Facility (SCF)-AIIMS, New Delhi (July 2019 to March 2020)

Invited Talks and Presentations

Dr. Mir has delivered oral presentations at various prestigious conferences and workshops, including:

• Workshops on regenerative medicine organized by AIIMS and Indiana University School of Medicine (2020).

·   National Conference on Recent Advances in Biological Sciences (NCRABS-2020)’’ organized by the Department of Biosciences JMI University, New Delhi.

He has also presented posters at international events like American Association of Cancer Research, International Congress of Cell Biology and the Society for Ethnopharmacology.

Mentorship and Scientific Community Participation

Dr. Mir has mentored several M.Sc. and M.Pharm students during his academic career and supervised six dissertation projects. At NIH, he participated as a judge for the 2024 Postbac Poster Day and reviewed over 20 research articles for peer-reviewed journals. His memberships include the American Association of Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).

Workshops and Community Involvement

Dr. Mir has completed advanced training in cancer immunology, genome editing (CRISPR), and flow cytometry. He actively contributes to the scientific community through collaborations and public outreach, including participating in podcasts and sharing insights on platforms like ResearchGate, LinkedIn, and Google Scholar.

Dr. Sameer Mir continues to innovate in cancer immunotherapy, striving to bridge the gap between laboratory research and clinical applications to benefit patients worldwide.